Day One Biopharmaceuticals Reports Q2 2025 Financial Results and Strategic Appointments.

Day One Biopharmaceuticals reported a 310% YoY increase in Q2 2025 OJEMDA revenue to $33.6 million, a 10% increase from Q1 2025. OJEMDA prescriptions exceeded 1,000 in Q2 2025, a 346% growth YoY. Despite the gains, the company reported a net loss of $30.3 million. Day One's cash position remains strong at $453.1 million, and they appointed Dr. Michael Vasconcelles as Head of Research and Development to enhance their oncology expertise.

Day One Biopharmaceuticals (DAWN) has reported robust financial results for the second quarter of 2025, highlighting significant growth in its OJEMDA revenue. The company's OJEMDA revenue surged by 310% year-over-year (YoY) to $33.6 million, marking a 10% increase from the previous quarter. This impressive performance reflects a 346% YoY growth in the number of OJEMDA prescriptions, which exceeded 1,000 in Q2 2025.

Despite these gains, Day One reported a net loss of $30.3 million in Q2 2025, which is a significant increase from the $4.4 million loss in Q2 2024. The company's cash position remains strong, with $453.1 million as of June 30, 2025. Additionally, Day One appointed Dr. Michael Vasconcelles as the new Head of Research and Development to bolster its oncology expertise.

The company has provided full-year 2025 net product revenue guidance of $140 million to $150 million for OJEMDA. This guidance is based on continued adoption through new patient starts and persistence on therapy, with a focus on expanding breadth and depth of prescribing and optimizing treatment duration. The company's commercial team is also focusing on managing adverse events to reduce dropouts and enhance patient success.

Research and Development (R&D) expenses saw a reduction to $36.1 million from $92.1 million in Q2 2024, primarily due to the upfront payment for MabCare's license in the prior year. The company discontinued its VRK1 program while advancing the PTK7-targeted ADC, DAY301, through Phase Ia dose escalation.

In summary, Day One Biopharmaceuticals demonstrated significant commercial momentum for OJEMDA in Q2 2025, with strong physician adoption and expanding patient access. The company is confident in its ability to solidify OJEMDA as a standard of care in relapsed/refractory pLGG and advance its pipeline, while maintaining a robust financial position to support long-term growth.

References:
[1] https://seekingalpha.com/news/4479302-day-one-biopharmaceuticals-non-gaap-eps-of-0_29-beats-by-0_05-revenue-of-33_91m-misses-by
[2] https://www.gurufocus.com/news/3036980/day-one-reports-second-quarter-2025-financial-results-and-corporate-progress-dawn-stock-news